Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Ladenburg Thalmann Downgrades NextCure to Neutral

Ladenburg Thalmann Downgrades NextCure to Neutral

Ladenburg Thalmann analyst Aydin Huseynov downgrades NextCure (NASDAQ:NXTC) from Buy to Neutral.

byBenzinga Newsdesk

November 4, 2022

1 minute read

Ladenburg Thalmann analyst Aydin Huseynov downgrades NextCure (NASDAQ:NXTC) from Buy to Neutral.

Mizuho Downgrades LyondellBasell Industries to Neutral, Announces $88 Price Target

By Benzinga Newsdesk

November 15, 5:22 AM

Mizuho analyst Christopher Parkinson downgrades LyondellBasell Industries (NYSE:LYB) from Buy to Neutral and announces $88 price target.

LYB

Analyst Ratings

The Latest Analyst Ratings for Ventyx Biosciences

By Benzinga Insights

November 10, 5:00 PM

Analysts have provided the following ratings for Ventyx Biosciences (NASDAQ:VTYX) within the last quarter: Bullish Somewhat Bullish Indifferent…

VTYX

MongoDB And Some Other Big Stocks Moving Higher In Today’s Pre-Market Session

By Lisa Levin

December 7, 7:11 AM

U.S. stock futures traded slightly lower this morning. Here are some big stocks recording gains in today’s pre-market trading session.

EGIO

CORRECTION: Vivos Therapeutics Q3 EPS $(0.26), Same YoY, Sales $4.25M Beat $3.72M Estimate

By Benzinga Newsdesk

December 20, 5:36 PM

Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.26) per share. This is unchanged from the same period last year. The company reported quarterly sales of $4.25 million which beat the analyst consensus

VVOS

Ladenburg Thalmann Downgrades NextCure to Neutral

Related Posts

Mizuho Downgrades LyondellBasell Industries to Neutral, Announces $88 Price Target

The Latest Analyst Ratings for Ventyx Biosciences

MongoDB And Some Other Big Stocks Moving Higher In Today’s Pre-Market Session

CORRECTION: Vivos Therapeutics Q3 EPS $(0.26), Same YoY, Sales $4.25M Beat $3.72M Estimate